Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Piramal Pharma Limited Announces Results for Q1 FY27
MUMBAI, India, July 29, 2026 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30…
Gland Pharma gets U.S. FDA nod for Sugammadex injection
Shares of Gland Pharma were in the spotlight on Tuesday, rising more than 4%, after the Hyderabad-based generic injectable drugmaker got the U.S. Food and Drug Administration (FDA) approval for its abbreviated new drug application for Sugammadex…
'It is okay not to be okay': NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness
For decades, pharmaceutical advertising largely revolved around television commercials urging patients to ask their doctors about branded medication. Increasingly, however, drugmakers are investing in a different kind of marketing…
NewAmsterdam Pharma (NAMS) Projected to Announce Earnings on Wednesday
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.48) per share and revenue of $1.8770 million for the…
Royalty Pharma (RPRX) Projected to Release Earnings on Wednesday
Royalty Pharma (NASDAQ:RPRX - Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $1.27 per share and revenue of $758.9270 million…
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of 'Moderate Buy' from Analysts
Urogen Pharma (NASDAQ:URGN - Get Free Report) has been assigned an average rating of 'Moderate Buy' from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock…
Nvidia's $5 Billion SSI Bet Could Protect Its Post-LLM Lead (NASDAQ:NVDA)
Nvidia Corporation invests $5B in Safe Superintelligence, Inc. to gain privileged access to frontier AI research and future workload insights. NVDA's strategic rationale centers on closing its research feedback loop, countering hyperscaler…
ICON Public Limited Company (ICLR) Surges on Net Book-to-Bill Strength
Harris Oakmark recently released its second-quarter 2026 investor letter for the 'Oakmark U.S. Concentrated Strategy'. A copy of the letter can be downloaded here. The strategy returned 9.21% (net) in the second quarter, lagging the Russell 1000…
Valitic Surpasses 2 Million Trusted Customers, Marking a Major Milestone in Its Consumer Wellness Growth
The rapidly growing skincare brand continues to strengthen its position in the U.S. beauty market through innovation, quality, and customer trust. HERZLIYA, Israel and CALGARY, AB, July 29, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE:…
Brazil approves generic GLP-1 drug sold by Swiss firm Sandoz
According to the statement, the Brazilian medicines regulator Anvisa has authorised the product Owozy for the treatment of type 2 diabetes. The product is being developed by Adalvo and will be marketed by Sandoz in Brazil. The market launch is…
War and drought: Another critical oil waterway is about to close
You have reached your maximum number of saved items. Remove items from your saved list to add more. With apologies to Oscar Wilde, to lose one critical waterway may be regarded as misfortune; to lose two looks like carelessness. Of course, we're…
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
The psychedelic medicine field looks like it's finally about to take off, and that's catching the attention of portfolio managers like Cathie Wood. Eli Lilly (LLY +2.00%) agreed on July 16 to acquire the biotech AtaiBeckley (ATAI +0.14%) for a $2.8…
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Novo Nordisk shareholders allege the company misled investors about a key clinical trial for its next-generation weight-loss drug CagriSema. A U.S. judge on Tuesday allowed parts of that lawsuit to move forward. Novo has viewed CagriSema as an…
State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?
Determining whether State Street Health Care Select Sector SPDR ETF (XLV +2.36%) or First Trust NYSE Arca Biotechnology Index Fund (FBT +1.85%) fits a portfolio depends on an investor's preference for broad-sector stability or concentrated…
Teva Pharmaceutical Industries Sees Unusually High Options Volume (NYSE:TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) saw unusually large options trading on Wednesday. Traders acquired 23,688 call options on the stock. This represents an increase of approximately 136% compared to the average daily…
Receive a Daily briefing on Pharma Industry News
Get Started